EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1

Ryan Choi iD, Matthew A Hulverson, Deborah A Schaefer, Dana P Betzer, Michael W Riggs, Wenlin Huang, Vicky Sun, Grant R Whitman, Molly C McCloskey, Kennan Marsh, Wayne R Buck, David S Wagner und 11 weitere

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0013263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Ryan Choi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Disease (CERID), University of Wa…. Hauptthemen laut MEDLINE: Cryptosporidiosis, Cryptosporidium parvum, Antiprotozoal Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Disease, National Institute of Child Health and Human Development, National Institute of Food and Agriculture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diarrheal pathogens, such as Cryptosporidium, impose a heavy burden of disease in resource-limited regions. Cryptosporidiosis often causes chronic infection in immunocompromised people and gastrointestinal injury in malnourished children, leading to wasting, stunting, and cognitive impairment. Current treatment for cryptosporidiosis fails in these vulnerable populations, highlighting the need for new medicines. Here we describe the anti- Cryptosporidium efficacy, pharmacokinetics, and safety of a bumped kinase inhibitor BKI-1708. BKI-1708 inhibits the essential molecular target, calcium-dependent protein kinase 1 (CDPK1), which is highly expressed in the major proliferative stages of the parasite life cycle. Methods and Findings Efficacy was demonstrated in the Cryptosporidium parvum IFNγ-KO mouse infection and calf diarrhea models. Dose response in the mouse model demonstrated oral doses as low as 15 mg/kg administered daily for 3 days completely suppressed oocyst shedding. Metabolite profiling in pre-clinical species and human hepatocytes identified an active metabolite, M2, which retains sub-micromolar activity against C. parvum . Pharmacokinetic analysis of BKI-1708 and M2 in mice demonstrates good systemic exposure, important for treating biliary and upper respiratory infections in some cases of cryptosporidiosis. In mice, M2 reaches 7-fold and >3-fold higher levels over BKI-1708 in plasma and the gastrointestinal tract, respectively. Oral administration of M2 completely suppressed oocyst shedding in the mouse model at doses as low as 8 mg/kg for 3 days. Wide safety margins are demonstrated in mice, rats, and dogs.

Conclusions

BKI-1708 has characteristics of a safe and effective drug for treating Cryptosporidium infections in animal models and shows promise for use in humans. Moreover, BKI-1708 and M2 formed in vivo, offer an attractive prospect of a dually active preclinical candidate for the treatment of cryptosporidiosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CryptosporidiosisCryptosporidium parvumAntiprotozoal AgentsProtein Kinase InhibitorsProtein KinasesProtozoan ProteinsAnimalsMiceDisease Models, AnimalHumansCattleMice, KnockoutFemaleDiarrheaMaleRatsCalcium-Calmodulin-Dependent Protein Kinases

Substanzen

Antiprotozoal AgentsProtein Kinase InhibitorsProtein KinasesProtozoan ProteinsCalcium-Calmodulin-Dependent Protein Kinases

Autor:innen und Institutionen

  • Department of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Disease (CERID), University of Washington, Seattle, Washington, United States of America.
  • School of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, Arizona, United States of America.
  • Department of Biochemistry, University of Washington, Seattle, Washington United States of America.
  • Department of Pharmaceutics, University of Washington, Seattle, Washington United States of America.
  • Research and Development, AbbVie Inc, North Chicago, Illinois, United States of America.
  • Cellular, Molecular and Biomedical Sciences Graduate Program, University of Vermont, Burlington, Vermont United States of America.

ORCID-Profile: Ryan Choi, Wesley C Van Voorhis

Förderung

  • National Institute of Allergy and Infectious Disease
  • National Institute of Child Health and Human Development
  • National Institute of Food and Agriculture
  • Bill and Melinda Gates Foundation
  • Swiss National Science Foundation
  • National Institute of Allergy and Infectious Diseases
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Choi, R., Hulverson, M. A., Schaefer, D. A., Betzer, D. P., Riggs, M. W., Huang, W., Sun, V., Whitman, G. R., McCloskey, M. C., Marsh, K., Buck, W. R., Wagner, D. S., Yang, J., Bowman, A. P., Ciurlionis, R., Ajiboye, J., Hemphill, A., Sigalapalli, D. K., Arnold, S. L. M., …, & Van Voorhis, W. C. (2025). Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013263

Vancouver

Choi R, Hulverson MA, Schaefer DA, Betzer DP, Riggs MW, Huang W, et al. Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013263

BibTeX
@article{Choi2025,
  author = {Choi, Ryan and Hulverson, Matthew A and Schaefer, Deborah A and Betzer, Dana P and Riggs, Michael W and Huang, Wenlin and Sun, Vicky and Whitman, Grant R and McCloskey, Molly C and Marsh, Kennan and Buck, Wayne R and Wagner, David S and Yang, Junhai and Bowman, Andrew P and Ciurlionis, Rita and Ajiboye, Jubilee and Hemphill, Andrew and Sigalapalli, Dilep K and Arnold, Samuel L M and Barrett, Lynn K and Ojo, Kayode K and Fan, Erkang and Van Voorhis, Wesley C},
  title = {Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0013263}
}
Kostenlos starten →